Trial Profile
Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2021
Price :
$35
*
At a glance
- Drugs Cabiralizumab (Primary) ; Nivolumab (Primary)
- Indications Cancer metastases; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Sep 2021 Status changed from completed to discontinued due to PI departure from institution.
- 25 Jun 2020 Status changed from recruiting to completed.
- 25 Nov 2019 Planned End Date changed from 1 Aug 2022 to 20 Jul 2020.